3
Announcements
Trials
Browse
Landscape
Status
Completed
215
Terminated
88
Unknown
39
Recruiting
36
Withdrawn
18
Active not recruiting
17
Not yet recruiting
6
Suspended
3
No longer available
2
Available
1
Approved for marketing
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Neoplasms
7
Carcinoma, Non-Small-Cell Lung
7
Sarcoma
5
Pancreatic Neoplasms
5
Multiple Myeloma
5
Melanoma
5
Prostatic Neoplasms
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Ovarian Neoplasms
3
Lymphoma, Large B-Cell, Diffuse
3
Leukemia, Myeloid, Acute
3
Glioblastoma
3
Breast Neoplasms
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Recurrence
2
Primary Myelofibrosis
2
Non-Muscle Invasive Bladder Neoplasms
2
Neuroblastoma
2
Neoplasm Metastasis
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Follicular
2
Lymphoma
2
Head and Neck Neoplasms
2
Gastrointestinal Neoplasms
2
Colorectal Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Transitional Cell
2
Interventions
tisagenlecleucel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Available
×
INDUSTRY
×
Leukemia
×
Clear all
NCT03601442
2026-04-23
Managed Access Programs for CTL019, Tisagenlecleucel
Novartis
Available